How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

238 results for

Emergency Pediatric Dosing 12-14 kilogram

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Emergency Pediatric Dosing 3 Kilogram

Emergency Pediatric Dosing 3 Kilogram Emergency Pediatric Dosing 3 Kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Emergency (...) Pediatric Dosing 3 Kilogram Emergency Pediatric Dosing 3 Kilogram Aka: Emergency Pediatric Dosing 3 Kilogram , Broselow Grey 3 kg II. Criteria: Body habitus Age: 0-2 months Length: 46-52 cm Weight: 3 kg III. Findings: Vital Signs (normal) : 90-165/minute : 40-60/minute Systolic : 40-60 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Pretreatment 0.1 mg Induction (Sedation) 0.9 mg 6 mg 9 mg Paralytic 6 mg 3 mg 0.3 mg Sedation Maintenance 0.15 mg Equipment ET Size

2015 FP Notebook

22. Emergency Pediatric Dosing over 36 kilogram

4 Emergency Pediatric Dosing over 36 kilogram Emergency Pediatric Dosing over 36 kilogram Aka: Emergency Pediatric Dosing over 36 kilogram , Broselow Over 36 kg II. Criteria: Body habitus Age: 13 years and older Weight >36 kg III. Findings: Vital Signs (normal) : 60-120/minute : 12-18/minute Systolic : 100-130 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Pretreatment 1.5 mg/kg 3 mcg/kg Induction (Sedation) 0.3 mg/kg (most common induction agent) 1.5 mg/kg (...) Emergency Pediatric Dosing over 36 kilogram Emergency Pediatric Dosing over 36 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration

2015 FP Notebook

23. Emergency Pediatric Dosing 24-28 kilogram

Emergency Pediatric Dosing 24-28 kilogram Emergency Pediatric Dosing 24-28 kilogram Aka: Emergency Pediatric Dosing 24-28 kilogram , Broselow Orange II. Criteria: Body habitus Age: 7-9 years Length: 122-137 cm Weight: 24-28 kg (mean 27 kg) III. Findings: Vital Signs (normal) : 60-120/minute : 12-25/minute Systolic : 90-115 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Induction (Sedation) 8 mg 53 mg 80 mg Paralytic 53 mg 27 mg 2.7 mg Sedation Maintenance 1.3 mg (...) Emergency Pediatric Dosing 24-28 kilogram Emergency Pediatric Dosing 24-28 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4

2015 FP Notebook

24. Emergency Pediatric Dosing 30-36 kilogram

Emergency Pediatric Dosing 30-36 kilogram Emergency Pediatric Dosing 30-36 kilogram Aka: Emergency Pediatric Dosing 30-36 kilogram , Broselow Green II. Criteria: Body habitus Age: 10-12 years Length: 137-150 cm Weight: 30-36 kg (mean 33 kg) III. Findings: Vital Signs (normal) : 60-120/minute : 12-25/minute Systolic : 95-120 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Induction (Sedation) 10 mg 66 mg 100 mg Paralytic 66 mg 33 mg 3.3 mg Sedation Maintenance 1.6 mg (...) Emergency Pediatric Dosing 30-36 kilogram Emergency Pediatric Dosing 30-36 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4

2015 FP Notebook

25. Emergency Pediatric Dosing 15-18 kilogram

Emergency Pediatric Dosing 15-18 kilogram Emergency Pediatric Dosing 15-18 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Emergency Pediatric Dosing 15-18 kilogram Emergency Pediatric Dosing 15-18 kilogram Aka: Emergency Pediatric Dosing 15-18 kilogram , Broselow White II. Criteria: Body habitus Age: 3-4 years Length: 97.5 to 110 cm Weight: 15-18 kg (mean 16.5 kg) III. Findings: Vital Signs (normal) : 75-135/minute : 20-30/minute Systolic : 80-110 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Induction (Sedation) 5 mg 33 mg 50 mg Paralytic 33 mg 17 mg 1.7 mg Sedation Maintenance 0.8

2015 FP Notebook

26. Emergency Adult Dosing 80 kilogram

Emergency Adult Dosing 80 kilogram Emergency Adult Dosing 80 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Emergency Adult (...) Dosing 80 kilogram Emergency Adult Dosing 80 kilogram Aka: Emergency Adult Dosing 80 kilogram II. Criteria: Body habitus Weight: 80 kg III. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Pretreatment 120 mg 250 mcg Induction (Sedation) 24 mg (most common induction agent) 120 mg (preferred in or ) 120 mg (avoid in ) 250 mg (rarely used for induction) 24 mg (rarely used for induction) Paralytic 120 mg 80 mg 8 mg Sedation Maintenance 4 mg Equipment ET Size cuffed (preferred

2015 FP Notebook

27. Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric (...) Identifier: NCT03185819 Recruitment Status : Recruiting First Posted : June 14, 2017 Last Update Posted : March 5, 2019 See Sponsor: Janssen Research & Development, LLC Information provided by (Responsible Party): Janssen Research & Development, LLC Study Details Study Description Go to Brief Summary: The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral

2017 Clinical Trials

28. Principles of Pediatric Patient Safety: Reducing Harm Due to Medical Care

of or method of using a treatment, 11% involved patient misidentification, and 7% involved delays or errors in diagnosis. , , Pediatric errors in emergency department (ED) settings may be attributable to multiple factors, including incorrect patient identification, lack of experience of many ED staff with pediatric patients versus with adults, and challenges with performing technical procedures in and calculating medication doses for children. , Other sources of error include communication between (...) of absorption and excretion ability, dependence on others for medication administration, and need for specially compounded formulations. Accurate weight scales that only measure in metric units (kilograms or grams), standardized equipment throughout a system, drug dose range limits, programmable “smart” infusion pumps for hospitals, and standardized order sets should be used. , Drug shortages have recently become an additional safety risk. Clinical pharmacists who are trained in pediatrics are invaluable

2019 American Academy of Pediatrics

29. The economic evaluation of early intervention with Anti-Tumor Necrosis Factor-alpha treatments in pediatric Crohn's disease

Incremental cost-utility ratio IFX Infliximab IM Immunomodulator ISPOR International Society For Pharmacoeconomics and Outcomes Research MOHLTC Ontario Ministry of Health and Long-Term Care kcal Calorie kg Kilogram mg Milligram MTA Material transfer agreement MTX Methotrexate NICE National Institute for Health and Care Excellence (United Kingdom) OCCI Ontario Case Costing Initiative OR Odds ratio PCDAI Pediatric Crohn’s Disease Activity Index PGA Physician Global Assessment QALY Quality-adjusted life year (...) Appendix 12. The Weighted Average Cost of Corticosteroids Per Week and Per Weight. 243 Appendix 13. The Weighted Average Cost of Antibiotics Per Week and Per Weight. 245 Appendix 14. The Weighted Average Cost of Oral 5-Aminosalicylates Per Week and Per Weight. 246 Appendix 15. The Mean Cost Per Week for Enteral Nutrition Supplements. 247 Appendix 16. Distribution of Imputed of Albumin. 249 Appendix 17. Propensity Score Differences in Unadjusted CD RISK-PROKIIDS Patient Population. 251 Appendix 18

2019 SickKids Reports

30. Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation

: Geoffrey W Jara-Almonte Information provided by (Responsible Party): Geoffrey W Jara-Almonte, New York Methodist Hospital Study Details Study Description Go to Brief Summary: Comparing one versus two doses of oral dexamethasone for the treatment of asthma in the pediatric emergency department. Condition or disease Intervention/treatment Phase Asthma Drug: Dexamethasone Drug: placebo Phase 3 Detailed Description: A randomized double blinded placebo controlled trial comparing one dose of dexamethasone (...) Controlled Trial of One Versus Two Doses of Oral Dexamethasone for the Treatment of Acute Asthma Exacerbation in the Pediatric Emergency Department (ED) Study Start Date : November 2015 Actual Primary Completion Date : November 2017 Actual Study Completion Date : November 2017 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Control Patients are given one dose of oral dexamethasone 0.6

2016 Clinical Trials

31. Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock

. 10 Department of Pediatrics, Baylor College of Medicine, Houston, TX. 11 Department of Pediatrics, Saint Barnabas Medical Center, Livingston, NJ. 12 Division of Emergency Medicine and Center for Pediatric Clinical Effectiveness, University of Pennsylvania Perelman School of Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA. 13 Intensive Care & Bioethics, Great Ormond St Hospital for Sick Children, London, United Kingdom. 14 Pediatric Critical Care Medicine, Department of Pediatrics (...) Educational and Scientific Symposia (2006–2014). The PubMed/Medline/Embase literature (2006–14) was searched by the Society of Critical Care Medicine librarian using the keywords: sepsis, septicemia, septic shock , endotoxemia, persistent pulmonary hypertension, nitric oxide, extracorporeal membrane oxygenation, and American College of Critical Care Medicine guidelines in the newborn and pediatric age groups. Measurements and Main Results: The 2002 and 2007 guidelines were widely disseminated, translated

2017 Society of Critical Care Medicine

32. Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures

and anxiolysis, the need for sedation for procedures in physicians’ offices, dental offices, subspecialty procedure suites, imaging facilities, emergency departments, other inpatient hospital settings, and ambulatory surgery centers also has increased markedly. 1–52 In recognition of this need for both elective and emergency use of sedation in nontraditional settings, the American Academy of Pediatrics (AAP) and the American Academy of Pediatric Dentistry (AAPD) have published a series of guidelines (...) /electroence- phalography. EMS: Emergency medical services. LMA: Laryngeal mask airway. MRI: Magnetic resonance imaging. OSA: Obstructive sleep apnea. PALS: Pediatric advanced life support. Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures: Update 2016 Developed and Endorsed by American Academy of Pediatric Dentistry and American Academy of Pediatrics Latest Revision* 2016 * This guideline was originally adopted in 2006

2016 American Academy of Pediatric Dentistry

33. Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

-normalized Parenteral Nutrition (PN) Fluid Volume at Week 24 [ Time Frame: From baseline up to Week 24 ] Number of participants who achieve at least a 20% reduction from baseline in weight-normalized average daily PN volume at Week 24/ end of treatment (EOT) will be summarized by treatment arm. Plasma Concentration of Teduglutide [ Time Frame: Pre-dose; 1, 4 hours post-dose, and 2 hours post-dose on Week 7 or 12 ] Plasma Concentration as a Pharmacokinetic parameter of Teduglutide will be assessed (...) of the first dose of investigational product. Change From Baseline in Body Weight Z-Score [ Time Frame: Baseline, Week 1,Week 3, Week 5, Week 7, Week 9, Week 12, Week 16, Week 20, Week 24 and Week 28 ] The Z-score indicates the number of standard deviations away from the mean. Change From Baseline in Length Z-Score [ Time Frame: Baseline, Week 5, Week 12, Week 16, Week 20, Week 24 and Week 28 ] The Z-score indicates the number of standard deviations away from the mean. Change From Baseline in Head

2018 Clinical Trials

34. Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

;graft dysfunction No difference in survival4 of 10 with hemodynamic compromise 11 1995 Ratliff Immunopathology 53 4–6 wk 11% of patients … … 12 1998 Behr Immunopathology 45 < 3 mo 60% of patients Survival No difference in survival 13 1999 Behr Immunopathology 56 < 3 mo 71% of patients Survival Survival worse with AMR (6 deaths in C4d+ group vs 3 deaths in C4d− group and 6 deaths in fibrin-positive group vs 3 deaths in fibrin-negative group) 14 1999 Baldwin Histopathology and immunopathology 24 7–24 (...) ); (28, 33, 34); (7, 15, 23); (3, 26); (12, 13); (14, 20). ACR indicates acute cellular rejection; AMR, antibody-mediated rejection; CAV, coronary allograft vasculopathy; DSA, donor-specific antibody; MICA, major histocompatibility complex class I chain–related antigen A; OR, odds ratio; PRA, panel reactive antibody; and RR, relative risk. * Immunopathology screening routinely on all cases. † Immunopathology screening strategy outside of study not specified. Risk Factors Reported risk factors for AMR

2015 American Heart Association

35. A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation

Time 0 to Infinity for TAK-536 [ Time Frame: Day 1 pre-dose and at multiple time points post-dose (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, and 48 hours post-dose; up to 48 hours) ] Terminal Disposition Phase Rate Constant (λz) for TAK-536 [ Time Frame: Day 1 pre-dose and at multiple time points post-dose (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, and 48 hours post-dose; up to 48 hours) ] Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs (...) Study of TAK-536 Pediatric Formulation The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03042299 Recruitment Status : Completed First Posted : February 3, 2017 Results First Posted : October 8, 2018 Last Update Posted : November 14, 2018 Sponsor: Takeda Information provided by (Responsible Party

2017 Clinical Trials

36. Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease Actual Study Start Date : July 30, 2018 Estimated Primary Completion Date : February 8, 2025 Estimated Study Completion Date : June 14, 2025 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go (...) to Arm Intervention/treatment Experimental: Vedolizumab High Dose Group Participants with UC or CD having baseline weight of greater than or equal to (>=) 30 kilogram (kg) will receive Vedolizumab 300 milligram (mg) and participants with UC or CD having baseline weight of less than (<) 30 kg will receive Vedolizumab 200 mg, intravenous infusion, every 8 weeks for up to 5 years. Drug: Vedolizumab Vedolizumab intravenous infusion. Other Names: MLN0002 ENTYVIO KYNTELES Experimental: Vedolizumab Low Dose

2017 Clinical Trials

37. Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting

: Arms and Interventions Go to Arm Intervention/treatment Experimental: SHP615 Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures. Drug: SHP615 SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg). Other Names: MHOS Midazolam hydrochloride oromucosal solution Drug: MHOS/SHP615 MHOS/SHP615 Outcome Measures (...) and the occurrence of buccal irritation will be assessed. Number of Participants with Treatment-emergent Adverse Events (TEAEs) [ Time Frame: From start of study drug administration up to Week 1 ] An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational

2017 Clinical Trials

38. Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Thai Pediatric Surgical Patients

, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 1 Year to 6 Years (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Inpatient who scheduled for non-emergency surgery Aged between 1 - 6 years Healthy volunteer Body weight more than 4.5 kilograms Opioid naive Schedule for pediatric non- GI tract surgery Exclusion (...) and noroxycodone) with specific respect to the pharmacogenomics (How drug affects patients). A total of 20 generally healthy, opioid-naive children, aged 1-6 years, scheduled as in-patient surgery for non-emergency surgery, non-gastrointestinal tract surgery are involved. The patients are divide into 2 groups (1) 10 patients in 12 months - 1.9 years, and (2) 10 patients in the 2 - 5.9 years age group. Every patient will receive inhalational or intravenous induction of anesthesia as decided by the anesthesia

2017 Clinical Trials

39. Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

milligram per kilogram (mg/kg) (Age Group 1: greater than or equal to [>=] 28 days and less than [<] 3 months of age), 6 mg/kg (Age Group 2: >=3 months and <6 months of age) and 9 mg/kg (Age Group 3: >=6 months and less than or equal to [<=3] years of age) orally once daily on Day 1 to Day 7. Drug: JNJ-53718678 Participants will receive of JNJ-53718678 (high dose or low dose) orally once daily for 7 days. Experimental: Low Dose: JNJ-53718678 Participants will be randomized to receive JNJ-53718678 1.7 mg (...) must be medically stable in case of allowed co-morbid conditions Exclusion Criteria: The participant is less than (<) 3 months postnatal age at screening and was born prematurely (i.e, <37 weeks and 0 days of gestation) OR if the participant weights <2.4 kilogram (kg) or greater than or equal to (>=) 16.8 kg Participant is considered by the investigator to be immunocompromised within the past 12 months Participant unwilling or unable to undergo mid-turbinate nasal swab procedures Participant

2018 Clinical Trials

40. Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Phase, during which participants will be assessed for eligibility, will consist of up to a 4-week ± 3 day Screening/Baseline Period. The Treatment Phase will consist of 3 periods: up to an 11-week Titration Period (dose titration on the basis of individual clinical response and tolerability), up to a 12-week Maintenance Period (continuation of perampanel oral suspension once daily at the dose level achieved at the end of the Titration Period), and up to a 4-week Follow-up Period (only for those (...) . Treatment of participants in Extension B will be completed when the participant reaches 12 years of age or when perampanel is commercially available in Japan for treatment of POS in pediatric participants (4 to <12 years of age). Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 160 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open-Label, Multicenter

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>